 |
|
News from Cancer: Risk factors for deadly form of lymphoma
July 07, 2008A new study indicates that the incidence of mantle cell lymphoma, an aggressive type of non-Hodgkin's lymphoma, is on the rise, most frequently striking men, Caucasians and older individuals. The study, published in the August 15, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society, also reveals that most patients are diagnosed with advanced stages of the disease.
While research has documented a steady increase in non-Hodgkin's lymphoma over the past several decades, the prevalence of mantle cell lymphoma, an uncommon yet distinct subtype of this cancer, remains unknown.
Mantle cell lymphoma was first established as a type of lymphoma in 1992. It is a fast-growing cancer of the immune system that is characterized by small- to medium-size cancer cells that may be in the lymph nodes, spleen, bone marrow, blood or gastrointestinal system. Despite the availability of many different types of therapies, the cancer remains incurable.
To determine how many people have been diagnosed with mantle cell lymphoma since it was first recognized, Dr. Michael Wang of the University of Texas M.D. Anderson Cancer Center and colleagues examined cancer registry data from 1992 to 2004, the most recent year for which complete data are available.
The researchers analyzed the records of 2,459 patients (2.8 percent of all patients with non-Hodgkin's lymphoma) diagnosed with mantle cell lymphoma during the time period. They found men were more than twice as likely to be diagnosed with the disease as women, and Caucasians had the highest risk of all ethnic groups. Age was a significant risk factor, with people between the ages of 70 to 79 more likely to be diagnosed with mantle cell lymphoma than all other age groups. The data also revealed that almost three-quarters of all mantle cell patients were diagnosed with advanced disease (stage III and IV).
When looking at trends during the study period, Drs. Wang and Du and their team found that the incidence rates increased progressively over time. In 1992, only 2.7 people per 1,000,000 were diagnosed, compared with 6.9 people per 1,000,000 in 2004. The investigators noted that the cause of this remarkable increase in the incidence rate of the disease over the past 13 years is unknown.
Because mantle cell lymphoma often goes undetected until later stages, it has the poorest prognosis of all lymphomas. Despite the recent discovery of new anti-cancer therapies that have improved the survival rates of patients with various types of non-Hodgkin's lymphoma, there is no clear standard approach for treating mantle cell lymphoma.
"A better understanding of the epidemiology of mantle cell lymphoma, the development of novel agents, more research funding and increased public awareness are all needed," the authors write.
American Cancer Society
To determine how many people have been diagnosed with mantle cell lymphoma since it was first recognized, Dr. Michael Wang of the University of Texas M.D. Anderson Cancer Center and colleagues examined cancer registry data from 1992 to 2004, the most recent year for which complete data are available.
The researchers analyzed the records of 2,459 patients (2.8 percent of all patients with non-Hodgkin's lymphoma) diagnosed with mantle cell lymphoma during the time period. They found men were more than twice as likely to be diagnosed with the disease as women, and Caucasians had the highest risk of all ethnic groups. Age was a significant risk factor, with people between the ages of 70 to 79 more likely to be diagnosed with mantle cell lymphoma than all other age groups. The data also revealed that almost three-quarters of all mantle cell patients were diagnosed with advanced disease (stage III and IV).
When looking at trends during the study period, Drs. Wang and Du and their team found that the incidence rates increased progressively over time. In 1992, only 2.7 people per 1,000,000 were diagnosed, compared with 6.9 people per 1,000,000 in 2004. The investigators noted that the cause of this remarkable increase in the incidence rate of the disease over the past 13 years is unknown.
Because mantle cell lymphoma often goes undetected until later stages, it has the poorest prognosis of all lymphomas. Despite the recent discovery of new anti-cancer therapies that have improved the survival rates of patients with various types of non-Hodgkin's lymphoma, there is no clear standard approach for treating mantle cell lymphoma.
"A better understanding of the epidemiology of mantle cell lymphoma, the development of novel agents, more research funding and increased public awareness are all needed," the authors write.
American Cancer Society
Lymphoma News and Current Lymphoma Events RSSNC State Is First University in Nation to Offer Canine Bone Marrow Transplants
Dogs suffering from lymphoma will be able to receive the same type of medical treatment as their human counterparts, as North Carolina State University becomes the first university in the nation to offer canine bone marrow transplants in a clinical setting.
VCU Massey Cancer Center Spearheads Novel Clinical Study for Lymphoma Patients
The Virginia Commonwealth University Massey Cancer Center recently opened a National Cancer Institute (NCI)-sponsored, phase II clinical study for certain sub-types of non-Hodgkin's lymphoma.
Researchers discover how rheumatoid arthritis causes bone loss
Researchers have discovered key details of how rheumatoid arthritis (RA) destroys bone, according to a study published in the Aug. 22 edition of the Journal of Biological Chemistry.
Duke chemists synthesize promising anti-cancer product
Duke University chemists have patented an efficient technique for synthesizing a marine algae extract in sufficient quantities to now test its ability to inhibit the growth of cancerous cells while leaving normal cells unaffected.
Children's national co-leads nationwide study of landmark sickle cell treatment
Children's National Medical Center immunologist and blood and marrow transplant physician Naynesh Kamani, MD, will serve as the study co-chair for a new national clinical trial of unrelated donor marrow and umbilical cord blood transplants for severe sickle cell disease.
Rheb's role in cancer
Two independent papers in the August 15th issue of G&D identify the Rheb GTPase as a novel oncogene and a promising new chemotherapeutic target.
Researchers find cancer-inhibiting compound under the sea
University of Florida College of Pharmacy researchers have discovered a marine compound off the coast of Key Largo that inhibits cancer cell growth in laboratory tests, a finding they hope will fuel the development of new drugs to better battle the disease.
Targeted drug therapy found effective in patients with common form of immune-mediated kidney disease
The drug rituximab causes considerable kidney injury healing in patients with membranous nephropathy, a common form of kidney disease, according to a study appearing in the November 2008 issue of the Clinical Journal of the American Society Nephrology (CJASN). The results suggest that this condition, previously destined to progress to kidney failure in 30-40 percent of cases, can actually be healed in some patients.
Exposure to Agent Orange linked to prostate cancer in Vietnam veterans
UC Davis Cancer Center physicians today released results of research showing that Vietnam War veterans exposed to Agent Orange have greatly increased risks of prostate cancer and even greater risks of getting the most aggressive form of the disease as compared to those who were not exposed.
New Guidelines for Treating Rheumatoid Arthritis
Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to guidelines issued by the American College of Rheumatology and co-authored by physicians at the University of Alabama at Birmingham (UAB).
More Lymphoma News Articles
 | Living with Lymphoma: A Patient's Guide by Elizabeth M. Adler "Adler's professional background and experience as a lymphoma survivor make her the perfect person to write this book. The author's explanations are a gentle guide and a thorough introduction to the basics that give us the confidence to handle decisions relating to treatments and other aspects of lymphoma." -- Anne Atkinson, non-Hodgkin lymphoma and Hodgkin disease survivor and coordinator of the... |
 | Ioachim's Lymph Node Pathology Now in its Fourth Edition, this comprehensive, practical, and thoroughly illustrated reference offers valuable guidance in the diagnostic interpretation of lymph node biopsies. It provides encyclopedic coverage of all the various nonmalignant lesions, lymphomas, other neoplasms, and metastatic tumors in lymph nodes. The discussion of each pathologic entity includes definition, clinical syndrome,... |
 | Non-Hodgkin's Lymphomas: Making Sense of Diagnosis, Treatment and Options by Lorraine Johnston Prior to publication of this resource guide, no book on the market targeted the non-Hodgkin's lymphoma survivor's need for understandable information. While there are medical texts on the non-Hodgkin's lymphomas as well as inspirational first-person accounts from survivors of related cancers such as leukemia, between these two sources of information existed a considerable information gap. In... |
 | 100 Questions & Answers About Lymphoma by Peter Holman, Jodi Garrett, William D. Jansen This book deals with lymphoma from a doctor's and a caregiver's... |
 | Salivary Gland Cytopathology (Essentials in Cytopathology) by William C. Faquin, Celeste N. Powers Salivary gland cytopathology is one of the most challenging areas of diagnostic cytology. Salivary Gland Cytopathology will use a simplified algorithmic approach based upon differential diagnostic groups to cover practical aspects of diagnosing common as well as challenging salivary gland lesions. This volume published in the “Essentials in Cytopathology” book series will fulfill... |
 | Bald in the Land of Big Hair: A True Story by Joni Rodgers Bald in the Land of Big Hair is the hilarious-and often heartbreaking-tale of Joni Rodgers's journey through the badlands of cancer told with humor, occasional anger, and unflinching honesty. More than just a cancer book, this is a deeply affecting memoir of one woman's struggle to come to terms with everything that life throws her way.Ultimately, this is a moving celebration of the true meaning... |
 | Surviving Has Made Me Crazy by Mark Nepo Poet and philosopher Mark Nepo was diagnosed with a rare form of lymphoma in 1987. His journey back to health awakened a new life. In his latest book, Nepo explores how sacred and useful everything is. As such, this book is for everyone, not just for those facing illness or pursuing poetry. The poems affirm that surviving has more to do with our authenticity than our longevity. The sixty-eight... |
 | Patient Number One: A True Story of How One CEO Took on Cancer and Big Business in the Fight of His Life by Rick Murdock, David Fisher Cancer is a terrorist, driving us mad with feelings of hopelessness and despair. One man, faced with lymphatic cancer and a poor prognosis, had the unique opportunity to influence not just the course of his treatment, but the research guiding that treatment. Patient Number One tells the story of Rick Murdock, former CEO of CellPro, a Seattle biotech company specializing in cell separation--as it... |
 | Hodgkin Lymphoma The definitive text on Hodgkin lymphoma is now in its thoroughly revised, updated Second Edition. More than 100 recognized authorities from all parts of the world provide comprehensive, current information on every aspect of Hodgkin lymphoma, including etiology, epidemiology, biology, pathology, evaluation, staging, treatment, and follow-up. This edition describes the increased use of PET... |
 | The Lymphomas by George P. Canellos, T. Andrew Lister, Bryan Young Edited and written by world authorities, this text encompasses all aspects of Hodgkin's disease, non-Hodgkin's lymphomas, and related disorders. Designed to be the "Bible" for both clinicians and scientists who deal with lymphoma, the book is packed with useful summary tables and abundant illustrations and translates cutting-edge discoveries into state-of-the-art management guidelines. The... |
| © 2008 BrightSurf.com |